Wire · operational-macro
First factor XIa inhibitor nabs FDA approval for stroke prevention
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 November 2026 · Fusion42 review
The US FDA has approved Bayer's asundexian (Sunharbo), the first factor XIa inhibitor, for stroke prevention in patients with recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Asundexian is used alongside antiplatelet therapy and works by reducing pathological clot formation.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
You face a newly approved stroke prevention drug that changes the anticoagulant market rules. Your biotech or medtech startup must evaluate this competitor's mechanism and timing to adjust development or partnerships.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics